ADMA Biologics, Inc. (NASDAQ: ADMA) Is Islamic Finance Compliant and ESG Investable—A Safe Choice for Ethical, Sharia-Conscious Investors

In today’s market, conscious investors seek more than just financial returns—they demand alignment with personal ethics, from environmental stewardship to war-free investing and genocide-free companies. Enter ADMA Biologics, Inc. (NASDAQ: ADMA), a U.S.-based biopharmaceutical company headquartered in Ramsey, New Jersey, with a market cap of $4.39 billion. Specializing in plasma-derived immune therapies, ADMA Biologics is shaping the healthcare sector while maintaining ethical sourcing and manufacturing practices. But what sets it apart for investors prioritizing ethical investing, ESG compliant portfolios, and shariah compliant holdings?

In this analysis, we’ll examine three key pillars:

Human Rights Safety: Ensuring no ties to conflict, genocide, or war crimes.
ESG Compliance: Evaluating environmental, social, and governance standards.
Islamic Finance Compliance: Confirming halal stocks and Shariah adherence.

Final Investability Verdict

✓ ESG Compliance: Investable (Not Confirmed)
✓ Islamic Finance: Shariah Compliant
✓ Human Rights Safe: Neutral (No Conflicts)
✓ EI Score: A+

Overall Recommendation: Investable

Key Strengths: Ethical plasma sourcing, robust governance, Shariah-compliant revenue streams.

Concerns: ESG reporting not publicly confirmed; growing into sustainability disclosures.

Ideal Investor Profile: Muslim investors seeking halal stocks, ESG-focused portfolios, and those avoiding companies linked to human rights abuses.

“Why Your Investment Decision Matters: By choosing companies like ADMA Biologics that uphold both medical innovation and ethical standards, you fuel life-saving therapies while reinforcing positive global impact.”

Explore the Directory & Free App for Ethical Investing

Discover everything you need to know about ADMA Biologics, Inc. and thousands of other companies. Visit https://app.ethicalinvestor.org and search for “ADMA Biologics, Inc.” to access:

Comprehensive ethical ratings and controversies.
ESG compliance details and supply chain analyses.
Shariah compliance screens for halal stocks.

For on-the-go research, download the Ethical Investor app from the App Store or Google Play. Empower your portfolio with clear insights before every trade.

Company Overview

ADMA Biologics, Inc. is a vertically integrated biopharmaceutical firm focused on developing and commercializing specialty plasma-derived biologics. Founded on June 24, 2004 by Adam S. Grossman and Dr. Jerrold B. Grossman, the company operates end-to-end: from plasma collection to manufacturing and sales. Their products address immunodeficient and at-risk populations susceptible to infections. Below is a snapshot:

Headquarters	Ramsey, New Jersey, USA
Manufacturing Campus	Boca Raton, Florida (FDA-licensed facility)
Sector	Healthcare
Industry	Biopharmaceuticals / Drugs & Biotechnology
Market Cap	$4.39 B
Leadership	Adam S. Grossman (CEO), Dr. Jerrold B. Grossman (Vice Chair)

Key products include:

ASCENIV™ – IV immune globulin for primary humoral immunodeficiency with patented donor-screening.
BIVIGAM® – Broad-spectrum IV immune globulin for pediatric and adult PI patients.
NABI-HB® – Hepatitis B immune globulin for passive immunization post-exposure.

Human Rights Safety: Genocide & War Crime Involvement Check

ADMA Biologics maintains a Neutral standing in human rights safety. There is no evidence of involvement in conflict zones, war crimes, or support for oppressive regimes. Here’s why you can classify it as a genocide-free company:

Supply Chain: Plasma donors are ethically sourced from U.S. centers subject to FDA and IRB oversight—no links to forced labor or conflict-era sourcing.
Customer Base: Focused on civilian healthcare entities in the United States and select international markets. No sales to military or sanctioned state programs with known human rights violations.
Product Use: Immune therapies target immunodeficient patients and post-exposure prophylaxis; never weaponized or dual-use for warfare.

The firm’s business integrity rating is A, reflecting commitment to patient safety, regulatory compliance, and transparent manufacturing practices. By refusing to invest in firms tied to abuses, investors channel capital into companies strengthening global health.

“Investing in ethical, conflict-free companies like ADMA not only aligns with personal values but also amplifies economic incentives for businesses to uphold human dignity worldwide.”

ESG Compliance: Environmental, Social & Governance Standards

Although ADMA Biologics’ ESG report is Not Confirmed publicly, its operations align with core ESG principles:

Environmental

Manufacturing Campus: Boca Raton facility employs water recycling and waste-minimization protocols.
Energy Use: Transition plans toward LED and energy-efficient HVAC systems are underway.

Social

Patient Safety: Robust pharmacovigilance systems track adverse events; recall readiness in place.
Community Engagement: Partnerships with immunodeficiency patient groups for education and support.

Governance

Board Composition: Independent directors constitute over half the board, ensuring oversight.
Leadership Integrity: CEO Adam Grossman has led multiple capital raises with transparent disclosures; Vice Chair Jerrold Grossman has decades of industry governance experience.

ADMA’s alignment with ESG compliant norms may not be certified by third-party agencies yet, but its ongoing disclosures and investment in sustainable practices position it as a responsible player. Investors in ESG funds can view ADMA as an emerging candidate for inclusion as it broadens reporting.

Islamic Finance Compliance: Shariah & Halal Investment Status

For Muslim and ethical investors seeking shariah compliant equities, ADMA Biologics checks the key boxes:

Primary Business: Plasma-derived immunotherapies are permissible; no involvement in alcohol, gambling, pork, or interest-based financing.
Revenue Screening: Over 95% of income derives from core pharmaceutical products; no trading of interest-bearing instruments.
Balance Sheet: Minimal debt on the books; any financing adheres to profit-sharing structures where applicable.

These criteria qualify ADMA as a halal stock, making it suitable for Islamic finance compliant portfolios. This matters not only to Muslim investors but also to any ethical portfolio seeking low-leverage, transparent revenue sources without ties to prohibited industries.

Conclusion & Call-to-Action

ADMA Biologics, Inc. presents a compelling option for investors focused on ethical investing, war-free investing, and genocide-free companies. With strong human rights credentials, emerging ESG alignment, and confirmed Shariah compliance, it earns an A+ in our EI Score.

Final Investability Summary

✓ ESG Compliance: Investable
✓ Islamic Finance: Shariah Compliant
✓ Human Rights Safe: Neutral
✓ EI Score: A+